Please assess the completion status of the following clinical trial:

Trial Title: A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Curatively treated head and neck squamous cell cancer with T3-T4 and/or N2-N3 pathology, with or without other findings of poor prognosis such as extranodal extension, positive resection margins, and perineural or vascular involvement~* Eastern Cooperative Oncology Group (ECOG) status of 0 to 2~Exclusion Criteria:~* Macroscopic residual disease after surgery~* Previous treatment with anti-epidermal growth factor receptor (anti-EGFR) targeted therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
- Placebo (Type: PLACEBO_COMPARATOR): Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).